MBM Commercial is delighted to have won Law Firm of the Year at the 2018/2019 LawNet Awards.

We are delighted to have won “Law Firm of the Year” for the second time in three years at the annual Law Awards of Scotland 2018.

MBM Commercial’s Corporate and Dispute Resolution Groups rank highly in this years Legal 500 and Chambers rankings.  The Corporate Group are listed in Band 4 for Corporate and Commercial: Edinburgh and Glasgow in Legal 500. “Under Kenny Mumford’s leadership, MBM Commercial has become a major player in the angel investment and venture capital arena, where it acts for investors and high-growth investee companies.” - Legal 500 “The firm is particularly well-known for its work in the technology sector (it has been active in the Scottish technology investment market for more than 12 years); it recently acted as a lead adviser...

An SME Finance Report has been issued by the Treasury Select Committee today evaluating what needs to be done in terms of addressing the deficiencies in the SME finance market. MBM Commercial’s Cat MacLean appeared before the Treasury Select Committee in May as an expert witness, providing evidence on SME finance at the Financial Services Tribunal. This Tribunal questioned the behaviour of the banks, particularly around resolving disputes and whether there is a need for a financial tribunal system. Cat MacLean heads up MBM’s Dispute Resolution Team, and has been litigating against large financial institutions since 2008. She is a...

MBM Commercial recently assisted with Archangels’ investment in MGB Biopharma to support the global fight against C. difficile . A novel anti-bacterial agent which has been developed in Scotland by MGB Biopharma (MGB) for the treatment of Clostridium difficile infections, is to enter Phase II clinical trials following a newly-completed £1.3m fund raise from existing and new investors, supplementing a £2.7m grant awarded earlier this year by Innovate UK.  MGB’s lead drug, MGB-BP-3 was invented at the University of Strathclyde, Glasgow, and will now be tested in patients for the first time in the fight against Clostridium difficile-associated disease (CDAD)....